yingweiwo

L-Adrenaline

Alias: L-Adrenaline; Adrenaline; Epinephrine Bitartrate; Epinephrine Hydrochloride; Epinephrine Hydrogen Tartrate; L-epinephrine; Adrenalin; Levoepinephrine; Epitrate; Lyophrin; Medihaler-Epi
Cat No.:V1136 Purity: ≥98%
L-Adrenaline (L-epinephrine; Adrenalin; Levoepinephrine; Epitrate; Lyophrin; Medihaler-Epi), the levo-isomer of adrenaline, belongs to a group of the compounds known as catecholamines.
L-Adrenaline
L-Adrenaline Chemical Structure CAS No.: 51-43-4
Product category: Adrenergic Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1g
2g
5g
10g
25g
50g
Other Sizes

Other Forms of L-Adrenaline:

  • Adrenaline Sulfate
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Purity: ≥98%

Product Description

L-Adrenaline (L-epinephrine; Adrenalin; Levoepinephrine; Epitrate; Lyophrin; Medihaler-Epi), the levo-isomer of adrenaline, belongs to a group of the compounds known as catecholamines. In the body, epinephrine is a hormone and neurotransmitter that controls heart rate, blood vessel and air passage diameters, and metabolic changes, among other biological processes. The sympathetic nervous system's fight-or-flight response includes the release of epinephrine, which is essential. Chemically speaking, adrenaline belongs to a class of monoamines known as the catecholamines. The amino acids phenylalanine and tyrosine are converted into it by certain central nervous system neurons as well as by the chromaffin cells in the adrenal medulla.

Biological Activity I Assay Protocols (From Reference)
Targets
Adrenergic Receptor
ln Vitro
Compared to untreated control eyes, the iris and palatial body blood flow of one eye of twelve monkeys was reduced by five percent and nine percent, respectively, after a 25 microliter volume of 1% L-adrenergic borate solution was applied to the left side of one of the eyes. Twenty percent[1]. Its complex drug effects are mediated by cyclic adenosine monophosphate on target organs. Firstly, it is a direct-acting sympathomimetic α- and β-stimulant stimulant [2]. Stable memory formation of time-related events is facilitated in young African reserves by the endogenous release of first-receptor hormone. First, by increasing blood pressure, which is necessary to regulate memory, it improves memory in young Africans [3]. Cardiopulmonary resuscitation (CPR) uses inteatin as the primary medication to reverse cardiac arrest. Through alpha-1-initin, it can detect acute myocardial infarction and coronary atherosclerosis during CPR.[4]
ln Vivo
25 μL volume of 1% L-adrenergic borate solution administered to the left side of one eye of 12 monkeys reduced iris and palatial body blood flow by 59% and 59%, respectively, compared with untreated control eyes. 20%[1]. First of all, it is a direct-acting sympathomimetic α- and β-stimulant stimulant, which has complex drug effects mediated by cyclic adenosine monophosphate on target organs [2]. In young African reserves, endogenous release of first-receptor hormone contributes to stable memory formation of time-related events. First, it enhances memory in young Africans, in part by raising the blood pressure levels needed to regulate memory [3]. Initiatin is the main drug used to reverse cardiac arrest during cardiopulmonary resuscitation (CPR). Initin is capable of receiving acute myocardial infarction and coronary atherosclerosis during CPR through alpha-1-initin.[4]
Animal Protocol
Rats: Rats are immediately put back into the holding cage after receiving a subcutaneous injection of either saline (0.9%), glucose (250 mg/kg), or epinephrine (0.1 mg/kg) for the immunohistochemistry experiments[3].
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Following I.V. (intravenous) injection, epinephrine disappears rapidly from the blood stream. Subcutaneously or I.M. (intramuscular) administered epinephrine has a rapid onset and short duration of action. Subcutaneous (SC) administration during asthmatic attacks may produce bronchodilation within 5 to 10 minutes, and maximal effects may occur within 20 minutes. The drug becomes fixed in the tissues rapidly,.
The majority of the dose of epinephrine is seen excreted in the urine,. About 40% of a parenteral dose of epinephrine is excreted in urine as metanephrine, 40% as VMA, 7% as 3-methoxy-4-hydroxyphenoglycol, 2% as 3,4-dihydroxymandelic acid, and the rest as acetylated derivatives. These metabolites are excreted mainly as the sulfate conjugates and, to a lesser extent, the glucuronide conjugates. Only small amounts of the drug are excreted completely unchanged.
Intravenous injection produces an immediate and intensified response. Following intravenous injection, epinephrine disappears rapidly from the blood stream.
Following topical application of radiolabeled epinephrine to the eye in rabbits, highest concentrations of the drug in tissues and fluids other than the eye occurred in the pituitary gland, with lower concentrations in the intestine, fat, adrenal gland, kidney, heart, lung, spleen, ovary, pancreas, liver, uterus, muscle, brain, and serum. In humans, systemically absorbed epinephrine crosses the placenta but not the blood-brain barrier. Systemically absorbed epinephrine distributes into milk.
Epinephrine is not effective after oral admin because it is rapidly conjugated and oxidized in GI mucosa and liver. Absorption from sc tissues occurs slowly because of local vasoconstriction ... Absorption is more rapid after im than after sc injection ... Epinephrine is rapidly inactivated in the body.
In a prospective, randomized, five-way crossover study in rabbits, ... plasma epinephrine concentrations /were measured/ before, and at intervals up to 180 min after epinephrine administration by intramuscular or subcutaneous injection, or by inhalation, with intravenous epinephrine and intramuscular saline as the positive and negative controls, respectively. Maximum plasma epinephrine concentrations were higher, and occurred more rapidly, after intramuscular injection than after subcutaneous injection or inhalation, and were 7719+/-3943 (S.E.M.) pg/mL at 32.5+/-6.6 min, 2692+/-863 pg/mL at 111.7+/-30.8 min and 1196+/-369 pg/mL at 45. 8+/-19.2 min, respectively. Intravenous injection of epinephrine resulted in a plasma concentration of 3544+/-422 pg/mL at 5 min, and an elimination half-life (t(1/2)) of 11.0+/-2.5 min. In the saline control study, the endogenous epinephrine concentration peaked at 518+/-142 pg/mL. CONCLUSION: In this model, absorption of epinephrine was significantly faster after intramuscular injection than after subcutaneous injection or inhalation. The extent of absorption was satisfactory after both intramuscular and subcutaneous injections. Neither the rate nor the extent of absorption was satisfactory after administration by inhalation.
3 groups of 5 greyhounds received 1.5 ug/kg epinephrine 1:200,000 in either lidocaine 0.5%, bupivacaine 0.5% or 0.9% saline. Dogs were anesthetized and 40% of the allocated epinephrine solution was infiltrated beneath the perianal skin and each of the 4 quadrants of the rectal mucosa was injected with the remainder of the solution. Plasma epinephrine, lidocaine, bupivacaine, lactate, glucose and potassium concn were measured at 1, 2, 5, 10 and 30 min following infiltration. Peak plasma epinephrine concn were recorded 2 min following rectal mucosal infiltration in all 3 groups. Plasma epinephrine concn were significantly higher (p < 0.01) in the lidocaine group at 1 and 2 min following infiltration. Both plasma bupivacaine and lidocaine peaked 10 min after infiltration and thereafter tended to decr towards baseline concn. Plasma bupivacaine concn were significantly higher (p < 0.01) than plasma lidocaine concn throughout the study period. There were no significant differences in metabolic or biochemical indices within or between the 3 groups. However, both plasma glucose and lactate concn were elevated and peaked 10 min after infiltration, while plasma potassium concn remained unchanged throughout the study period. Heart rate in the bupivacaine group was significantly reduced at 30 min following infiltration (p < 0.05). There were no significant differences observed in the mean arterial and pulse pressures among the 3 groups.
Epinephrine is well absorbed after subcutaneous or IM injection; absorption can be hastened by massaging the injection site. Both rapid and prolonged absorption occur after subcutaneous injection of the longer-acting aqueous suspension (no longer commercially available in the US). Epinephrine also is absorbed following endotracheal administration, although serum concentrations achieved may be only 10% of those with an equivalent IV dose.. After oral inhalation of epinephrine in the usual dosage, absorption is slight and the effects of the drug are restricted mainly to the respiratory tract. Absorption increases somewhat when larger doses are inhaled, and systemic effects may occur.
Metabolism / Metabolites
Epinephrine is rapidly inactivated mainly by enzymic transformation to metanephrine or normetanephrine, either of which is then conjugated and excreted in the urine in the form of both sulfates and glucuronides. Either sequence results in the formation of 3-methoxy-4- hydroxy-mandelic acid(vanillylmandelic acid, VMA) which is shown to be detectable in the urine. Epinephrine is rapidly inactivated in the body mostly by the enzymes COMT (catechol-O-methyltransferase) and MAO (monoamine oxidase). The liver is abundant in the above enzymes, and is a primary, although not essential, tissue in the degradation process.
The pharmacologic actions of epinephrine are terminated mainly by uptake and metabolism in sympathetic nerve endings. Circulating drug is metabolized in the liver and other tissues by a combination of reactions involving the enzymes catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). The major metabolites are metanephrine and 3-methoxy-4-hydroxymandelic acid (vanillylmandelic acid, VMA) both of which are inactive. About 40% of a parenteral dose of epinephrine is excreted in urine as metanephrine, 40% as VMA, 7% as 3-methoxy-4-hydroxyphenoglycol, 2% as 3,4-dihydroxymandelic acid, and the remainder as acetylated derivatives. These metabolites are excreted mostly as the sulfate conjugates and, to a lesser extent, the glucuronide conjugates. Only small amounts of the drug are excreted unchanged.
Circulating epinephrine is metabolized in the liver and is taken up into adrenergic neurons and metabolized by MAO and catechol-O-methyltransferase to metadrenaline, sulfate conjugates, and hydroxy derivatives of mandelic acid.
Epinephrine has known human metabolites that include Epinephrine sulfate.
Biological Half-Life
The plasma half-life is approximately 2-3 minutes. However, when administered by subcutaneous or intramuscular injection, local vasoconstriction may delay absorption so that epinephrine's effects may last longer than the half-life suggests.
Elimination half life is 1 minute.
Toxicity/Toxicokinetics
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
No information is available on the use of epinephrine during breastfeeding. Because of its poor oral bioavailability and short half-life, any epinephrine in milk is unlikely to affect the infant. High intravenous doses of epinephrine might reduce milk production or milk letdown. Low-dose intramuscular (such as Epi-Pen), epidural, topical, inhaled or ophthalmic epinephrine are unlikely to interfere with breastfeeding. To substantially diminish the effect of the drug after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue. Epinephrine is the first line-medication of choice for treatment of anaphylaxis; it should be used in the same manner in breastfeeding and non-breastfeeding patients.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information in nursing mothers was not found as of the revision date. Intravenous epinephrine infusion in nonnursing subjects and in women with hyperprolactinemia decreases serum prolactin concentrations. Animal data indicate that intraarterial epinephrine can decrease serum oxytocin and inhibit milk ejection. However, low-dose infusion of epinephrine as part of epidural analgesia does not impair breastfeeding in nursing mothers. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
An Egyptian study compared lidocaine 2% (n = 75) to lidocaine 2% plus epinephrine 1:200,000 (n = 70) as a wound infiltration following cesarean section. Patients who received epinephrine in combination with lidocaine began breastfeeding at 89 minutes following surgery compared to 132 minutes for those receiving lidocaine alone. The difference was statistically significant.
Interactions
Use in patients taking propranolol and other nonselective beta blockers may produce severe hypertension owing to blockade of beta-2-mediated vasodilation, resulting in unopposed alpha-vasoconstriction.
Epinephrine should not be administered concomitantly with other sympathomimetic agents because of the possibility of additive effects and increased toxicity.
Administration of epinephrine in patients receiving cyclopropane or halogenated hydrocarbon general anesthetics that increase cardiac irritability and seem to sensitize the myocardium to epinephrine may result in arrhythmias including PVCs, tachycardia, or fibrillation. Epinephrine is contraindicated for use with chloroform, trichloroethylene, or cyclopropane and should be used cautiously, if at all, with other halogenated hydrocarbon anesthetics such as halothane. Epinephrine may not be absorbed rapidly enough to cause serious adverse effects when applied topically as a hemostatic in patients undergoing short surgical procedures such as tonsillectomy and adenoidectomy using halothane anesthesia. Prophylactic administration of lidocaine or prophylactic IV administration of propranolol 0.05 mg/kg may protect against ventricular irritability if epinephrine is used during anesthesia with a halogenated hydrocarbon anesthetic. In one study, arrhythmias occurring after parenteral use of epinephrine during general anesthesia responded promptly to IV propranolol 0.05 mg/kg.
The effects of epinephrine 1/200,000 added to mg of epidural morphine were investigated in 3 healthy male volunteers, during 26 hr observation sessions. Cutaneous hypalgesia was intense, faster in onset, and longer in duration after epinephrine-morphine than after plain morphine. Apparently, epinephrine 1/200,000 reduces manifestations of cord and brainstem uptake. The need for the reduction of the customary dose of epidural morphine, while epinephrine is used as an adjuvant, is discussed.
For more Interactions (Complete) data for EPINEPHRINE (20 total), please visit the HSDB record page.
Non-Human Toxicity Values
LD50 Rat dermal 62 mg/kg
LD50 Rat sc 62 mg/kg
LD50 Rat iv 0.15 mg /kg
LD50 Rat im 3500 mg/kg
For more Non-Human Toxicity Values (Complete) data for EPINEPHRINE (9 total), please visit the HSDB record page.
References

[1]. The effect of topical l-epinephrine on regional ocular blood flow in monkeys. Invest Ophthalmol Vis Sci. 1980 May;19(5):487-91.

[2]. First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol. 2004 May;113(5):837-44.

[3]. Epinephrine and glucose modulate training-related CREB phosphorylation in old rats: relationships to age-related memory impairments. Exp Gerontol. 2013 Feb;48(2):115-27.

[4]. Epinephrine for cardiac arrest. Curr Opin Cardiol. 2013 Jan;28(1):36-42.

Additional Infomation
Therapeutic Uses
Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adrenergic Agonists; Bronchodilator Agents; Mydriatics; Sympathomimetics; Vasoconstrictor Agents
Epinephrine is the drug of choice in the emergency treatment of severe acute anaphylactic reactions including anaphylactic shock. Symptoms such as urticaria, pruritus, angioedema, and swelling of the lips, eyelids, and tongue which may result from reactions to drugs, sera, insect stings, food, or other allergens may be relieved by epinephrine. Epinephrine should be given to all patients with signs of systemic reactions, particularly hypotension, airway swelling, or definite breathing difficulty. Circulatory support during anaphylactic shock requires rapid volume resuscitation and vasopressor therapy to support blood pressure; epinephrine is the drug of choice for the treatment of both vasodilation/hypotension and cardiac arrest associated with anaphylaxis. /Included in US product label/
Epinephrine may be added to solutions of some local anesthetics to decrease the rate of vascular absorption of the anesthetic, thereby localizing anesthesia and prolonging the duration of anesthesia; the risk of systemic toxicity from the local anesthetic is also decreased. Epinephrine may be applied topically to control superficial bleeding from arterioles or capillaries in the skin, mucous membranes, or other tissues. Bleeding from larger vessels is not controllable by topical application of epinephrine. /Included in US product label/
Epinephrine is used for its a-adrenergic stimulatory effects to increase blood flow in advanced cardiovascular life support (ACLS) during cardiopulmonary resuscitation (CPR). The principal beneficial effects of the drug in patients with cardiac arrest result from increases in aortic diastolic blood pressure and in myocardial and cerebral blood flow during resuscitation. The value and safety of the beta-adrenergic effects of epinephrine are controversial because they may increase myocardial work and reduce subendocardial perfusion. Epinephrine remains a drug of choice and a high priority for ACLS in cardiac arrest to facilitate return of spontaneous circulation. /Included in US product label/
For more Therapeutic Uses (Complete) data for EPINEPHRINE (15 total), please visit the HSDB record page.
Drug Warnings
Epinephrine should not be used in cardiogenic shock because it increases myocardial oxygen demand, nor should it be used in hemorrhagic or traumatic shock.
Vet: epinephrine injection (1:1000): do not use in acute hypotension produced by phenothiazine derived tranquilizers, since further depression of blood pressure can occur. Do not use when cyclopropane or halogenated anesthetics are used because of possible cardiac collapse. Do not use in treatment of vascular shock. Do not use in patients known to be sensitive to epinephrine ... Use with caution in hyperthyroid animals; animals being treated with thyroid, digitalis, or mercurial diuretics. Do not use injection if it is brown or contains a precipitate.
A prospective study where topical epinephrine was used on burn and non-burn patients and five patients served as controls without epinephrine usage. Catecholamine concentrations were measured and to estimate the systemic effects of epinephrine, serum lactate and pyruvate concentrations were analyzed and perioperative haemodynamic changes recorded. Compared to the baseline values, there was a significant increase in the heart rate, serum epinephrine and lactate concentrations and LP-ratios in the burn patients and an increase in the epinephrine concentrations in the non-burn patients at 1 and 2 h. Epinephrine and lactate concentrations and LP-ratios were also higher in the burn patients compared to the other groups. Altogether, there were no changes in the control group. This study showed that the use of topical epinephrine has systemic effects on hemodynamics and serum epinephrine concentrations. Increased epinephrine concentrations in burn patients suggest increased absorption properties in these patients. The increased lactate concentrations and LP-ratios suggest tissue ischaemia, likely in skin.
Some manufacturers state that epinephrine is contraindicated for parenteral use during the second stage of labor; parenteral administration of the drug to maintain blood pressure during spinal anesthesia for delivery can cause acceleration of fetal heart rate and should not be used in obstetric patients when maternal systolic/diastolic blood pressure exceeds 130/80 mm Hg. Epinephrine should be administered cautiously by oral inhalation to pregnant patients. Epinephrine should be used during pregnancy only if the potential benefits justify the possible risks to the fetus. There is some evidence that epidural administration of lidocaine with epinephrine during labor is safe.
For more Drug Warnings (Complete) data for EPINEPHRINE (21 total), please visit the HSDB record page.
Pharmacodynamics
Epinephrine is a sympathomimetic drug. It causes an adrenergic receptive mechanism on effector cells and mimics all actions of the sympathetic nervous system except those on the facial arteries and sweat glands. Important effects of epinephrine include increased heart rate, myocardial contractility, and renin release via beta-1 receptors. Beta-2 effects produce bronchodilation which may be useful as an adjunct treatment of asthma exacerbations as well as vasodilation, tocolysis, and increased aqueous humor production. In croup, nebulized epinephrine is associated with both clinically and statistically significant transient reduction of croup symptoms 30 minutes post-treatment. Epinephrine also alleviates pruritus, urticaria, and angioedema and may be helpful in relieving gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxing effects on the smooth muscle of the stomach, intestine, uterus, and urinary bladder.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C9H13NO3
Molecular Weight
183.2
Exact Mass
183.089
Elemental Analysis
C, 59.00; H, 7.15; N, 7.65; O, 26.20
CAS #
51-43-4
Related CAS #
L-Epinephrine sulfate; 52455-32-0
PubChem CID
5816
Appearance
White to off-white solid powder
Density
1.3±0.1 g/cm3
Boiling Point
413.1±40.0 °C at 760 mmHg
Melting Point
208-211ºC
Flash Point
207.9±17.9 °C
Vapour Pressure
0.0±1.0 mmHg at 25°C
Index of Refraction
1.608
LogP
-0.63
Hydrogen Bond Donor Count
4
Hydrogen Bond Acceptor Count
4
Rotatable Bond Count
3
Heavy Atom Count
13
Complexity
154
Defined Atom Stereocenter Count
1
SMILES
O[C@H](C1=CC(O)=C(O)C=C1)CNC
InChi Key
UCTWMZQNUQWSLP-VIFPVBQESA-N
InChi Code
InChI=1S/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1
Chemical Name
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
Synonyms
L-Adrenaline; Adrenaline; Epinephrine Bitartrate; Epinephrine Hydrochloride; Epinephrine Hydrogen Tartrate; L-epinephrine; Adrenalin; Levoepinephrine; Epitrate; Lyophrin; Medihaler-Epi
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage.  (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.  (3). This product is not stable in solution, please use freshly prepared working solution for optimal results.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 2.2~4 mg/mL (12.1~21.8 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 5.4585 mL 27.2926 mL 54.5852 mL
5 mM 1.0917 mL 5.4585 mL 10.9170 mL
10 mM 0.5459 mL 2.7293 mL 5.4585 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Role of Adrenaline in in the Inflammatory Response in Diabetes
CTID: NCT05990933
Phase: N/A    Status: Completed
Date: 2024-11-21
The PAIN (Pelvic Area Injection for Numbness) Study
CTID: NCT05972681
Phase: Phase 4    Status: Recruiting
Date: 2024-11-12
Pharmacokinetics Study of DESF in Adults with Oral Allergy Syndrome
CTID: NCT06527937
Phase: Phase 2    Status: Completed
Date: 2024-11-05
Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?
CTID: NCT02276495
Phase: N/A    Status: Completed
Date: 2024-10-29
Epinephrine in Irrigation Fluid for Visualization During Ankle Surgery
CTID: NCT06264596
Phase: Phase 3    Status: Withdrawn
Date: 2024-10-15
View More

Intrathecal Dexmedetomidine Vs Epinephrine
CTID: NCT06418308
Phase: Phase 4    Status: Recruiting
Date: 2024-10-15


Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation
CTID: NCT05738148
Phase: Phase 1    Status: Recruiting
Date: 2024-09-19
Dose Response of Epinephrine
CTID: NCT02692313
PhaseEarly Phase 1    Status: Recruiting
Date: 2024-09-05
Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies
CTID: NCT03126968
Phase: Phase 2/Phase 3    Status: Completed
Date: 2024-08-28
Comparative Efficacy of Hypertonic Saline vs Adrenaline Nebulization in Acute Bronchiolitis
CTID: NCT06267118
Phase: Phase 3    Status: Recruiting
Date: 2024-08-22
Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.
CTID: NCT06013150
Phase: Phase 1    Status: Completed
Date: 2024-08-20
The Prevention of Hypotension After Epidural Analgesia After Major Surgery
CTID: NCT02722746
Phase: N/A    Status: Completed
Date: 2024-07-25
Epinephrine Vs Norepinephrine Infusion During Caesarean Delivery
CTID: NCT06512402
Phase: N/A    Status: Not yet recruiting
Date: 2024-07-22
Multimodal Orthognathic Study Comparing Use of Exparel With Standard of Care.
CTID: NCT06499181
PhaseEarly Phase 1    Status: Completed
Date: 2024-07-19
Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation
CTID: NCT06416969
PhaseEarly Phase 1    Status: Not yet recruiting
Date: 2024-07-19
Epinephrine Dose: Optimal Versus Standard Evaluation Trial
CTID: NCT03826524
Phase: Phase 4    Status: Recruiting
Date: 2024-07-12
Liposomal Bupivacaine Use in Alveolar Bone Graft Patients
CTID: NCT06284434
Phase: Phase 3    Status: Recruiting
Date: 2024-07-03
Comparison of the Effects of Two Concentrations of Adrenaline (0.33 mg/l vs 1 mg/l) in the Irrigation Serum of Arthroscopic Shoulder Surgery
CTID: NCT05439213
Phase: N/A    Status: Completed
Date: 2024-07-01
Early Resuscitation in Paediatric Sepsis Using Inotropes
CTID: NCT06478797
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-06-27
WALANT Versus Axillary Brachial Plexus Block in Carpal Tunnel Release
CTID: NCT06040840
Phase: N/A    Status: Recruiting
Date: 2024-05-28
The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA
CTID: NCT06112548
Phase: N/A    Status: Recruiting
Date: 2024-05-02
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
CTID: NCT01059786
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-05-01
The EPIVER Randomized Controlled Trial
CTID: NCT04573751
Phase: N/A    Status: Completed
Date: 2024-04-29
Epinephrine in the Pediatric Intensive Care Unit: A Dose-Effect Trial
CTID: NCT05327556
Phase: Phase 2    Status: Enrolling by invitation
Date: 2024-04-23
Distribution, Pharmacokinetics and Extent of Sensory Blockade in ESP Blocks
CTID: NCT03476642
Phase: Phase 4    Status: Completed
Date: 2024-04-16
Tranexamic Acid to Improve Arthroscopic Visualization in Shoulder Surgery
CTID: NCT04594408
Phase: Phase 4    Status: Completed
Date: 2024-04-02
Epinephrine Infusion for Prophylaxis Against Maternal Hypotension After Spinal Anesthesia for Cesarean Delivery
CTID: NCT05881915
Phase: N/A    Status: Completed
Date: 2024-02-28
POHCA Resuscitation: Evaluation of IM Epinephrine
CTID: NCT05166343
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2024-02-26
Comparing the Efficiency of Two Approaches in Patients at Risk of Developing Intraoperative Floppy Iris Syndrome
CTID: NCT06266962
Phase: Phase 4    Status: Completed
Date: 2024-02-20
Opioid-Free Pain Protocol After Shoulder Arthroplasty
CTID: NCT05488847
Phase: Phase 4    Status: Recruiting
Date: 2024-01-12
Bioavailability of Nasal Epinephrine
CTID: NCT04696822
Phase: Phase 1    Status: Completed
Date: 2024-01-05
Prophylactic Tranexamic Acid Versus Adrenaline During Flexible Bronchoscopy
CTID: NCT06145191
Phase: N/A    Status: Recruiting
Date: 2023-12-26
Vasoactive Drugs in Intensive Care Unit
CTID: NCT02118467
Phase: Phase 4    Status: Recruiting
Date: 2023-12-21
Multifidus Cervicis Plane Block Vs. Sham Block For Posterior Cervical Spine Fusion Surgery
CTID: NCT05996133
Phase: Phase 4    Status: Recruiting
Date: 2023-12-19
Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures
CTID: NCT02967172
Phase: Phase 4    Status: Completed
Date: 2023-12-15
Control of Iatrogenic Endobronchial Bleeding by Tranexamic Acid, Adrenalin and Hemagglutinase
CTID: NCT06149091
PhaseEarly Phase 1    Status: Recruiting
Date: 2023-11-28
Epinephrine to Prevent Postintubation Collapse in Shocked ICU Patients
CTID: NCT06115473
Phase: N/A    Status: Recruiting
Date: 2023-11-08
Lidocaine Irrigation in Shoulder Arthroscopy
CTID: NCT05624957
Phase: N/A    Status: Completed
Date: 2023-10-19
Topical Adrenaline Versus Warm Saline Solution for Minimizing Intraperitoneal Bleeding During Caesarian Delivery for Placenta Previa / Accreta Spectrum ( PAS)
CTID: NCT06030479
Phase: N/A    Status: Recruiting
Date: 2023-09-11
Comparative Effect of Palatal Injection in Pediatric Patient
CTID: NCT06025825
Phase:    Status: Recruiting
Date: 2023-09-06
Tranexamic Acid During Upper GI Endoscopic Resection Procedures
CTID: NCT05688020
Phase: Phase 4    Status: Recruiting
Date: 2023-08-09
Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults
CTID: NCT05152901
Phase: Phase 1    Status: Completed
Date: 2023-07-24
Effects of Adrenaline Infiltration on Surgical Field of View in Endoscopic Sinus Surgery
CTID: NCT05867342
Phase: Phase 4    Status: Completed
Date: 2023-07-10
Comparing the Hemodynamic Effects of Epinephrine Versus Dexmedetomidine as an Adjuvant to Bupivacaine in Caudal Anaesthesia Assessed by Cardiometry
CTID: NCT05860010
Phase: N/A    Status: Not yet recruiting
Date: 2023-05-16
Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes
CTID: NCT05095259
Phase: N/A    Status: Active, not recruiting
Date: 2023-05-03
The Effect of Buccal Infiltration Administration of Clonidine on the Success Rate of Inferior Alveolar Nerve Block
CTID: NCT04186299
Phase: Phase 4    Status: Withdrawn
Date: 2023-04-10
Epinephrine Nebulization Prior to Nasotracheal Intubation
CTID: NCT05738564
Phase: Phase 3    Status: Completed
Date: 2023-02-22
RCT of Gastric ESD With or Without Epineprhine Added Solution
CTID: NCT04032119
Phase: Phase 3    Status: Completed
Date: 2023-02-08
'The Effect Of Subcutaneous Epinephrine Dosage On Blood Loss In Surgical Incision'
CTID: NCT05670808
Phase: Phase 1    Status: Unknown status
Date: 2023-01-04
Management of Shock in Children With SAM or Severe Underweight and Diarrhea
CTID: NCT04750070
Phase: Phase 3    Status: Unknown status
Date: 2022-12-20
Efficacy of Intraoperative Injections on Postoperative Pain Control During Total Hip Replacement
CTID: NCT03119038
Phase: Phase 4    Status: Withdrawn
Date: 2022-10-27
The Effect of Epinephrine, Norepinephrine and Phenylephrine on Intraoperative Hemodynamic Performance
CTID: NCT05492968
Phase: Phase 4    Status: Unknown status
Date: 2022-10-19
Effect of Epinephrine on Post-polypectomy Pain
CTID: NCT04065451
Phase: Phase 4    Status: Completed
Date: 2022-09-30
Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries
CTID: NCT02980835
Phase: Phase 4    Status: Completed
Date: 2022-09-22
Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers
CTID: NCT03366298
Phase: Phase 4    Status: Completed
Date: 2022-09-07
Nebulized Epinephrine vs. Salbutamol in Bronchiolitis Among Children
CTID: NCT03814954
Phase: N/A    Status: Completed
Date: 2022-08-30
Peri-Incisional Drug Injection in Lumbar Spine Surgery
CTID: NCT03513445
Phase: Phase 3    Status: Withdrawn
Date: 2022-08-19
Impact of Intracoronary Versus Intravenous Epinephrine Administration During Cardiac Arrest .
CTID: NCT05253937
Phase:    Status: Completed
Date: 2022-08-16
Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
CTID: NCT05439460
Phase: Phase 4    Status: Completed
Date: 2022-08-05
Multi-Modal Anesthesia Protocol in Pain Management of Patients Undergoing Posterior Lumbar Spinal Fusion Surgery
CTID: NCT05413902
Phase: Phase 4    Status: Completed
Date: 2022-06-10
Peri-Articular-Multimodal Drug and Oral Celecoxib in Management of Postoperative Pain of Total Knee Arthroplasty
CTID: NCT05324995
Phase: Phase 2    Status: Completed
Date: 2022-04-14
Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty
CTID: NCT02570503
Phase: Phase 4    Status: Terminated
Date: 2022-03-04
Tranexamic Acid Versus Adrenaline for Controlling Iatrogenic Endobronchial Bleeding
CTID: NCT04771923
Phase: N/A    Status: Completed
Dat
Effect and safety of the iliopsoas plane block in healthy volunteers
CTID: null
Phase: Phase 2    Status: Completed
Date: 2018-04-24
The effect of the popliteal plexus block on postoperative pain after total knee arthroplasty - a randomized, controlled, double-blinded study
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2018-02-19
Pharmacokinetics of Intramuscular Adrenaline in Food-Allergic Teenagers
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-10-02
Combination of intrathecal morphine and local infiltration analgesia in treatment postoperative pain of total knee arthroplasty
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-09-14
The effect of the popliteal plexus block on postoperative pain after reconstruction of the anterior cruciate ligament
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-06-20
Postoperative analgesia after elective hip surgery - effect of obturator nerve blockade
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-05-24
Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjector application (Fastjekt® Junior) in infants with acute anaphylactic reaction during a food provocation
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2016-06-10
The effect of subsartorial saphenous block on postoperative pain following major ankle and hind foot surgery
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-04-05
Shamrock – Ultrasound/MR image fusion guided lumbar plexus blocks
CTID: null
Phase: Phase 2    Status: Completed
Date: 2016-02-08
PHASE II CLINICAL TRIAL FOR A STEPWISE PROGRESSION IN THE TREATMENT OF CARDIOGENIC SHOCK
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2015-04-20
Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care
CTID: null
Phase: Phase 1    Status: Not Authorised
Date: 2015-04-10
Protracted mixture of local anaesthetics for major foot and ankle surgery. A randomized double-blind, controlled study comparing Bupivacaine-epinephrine 0.5% and Bupivacaine-epinepherine 0.5% plus dexamethasone
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-04-08
Comparison of the effect of saphenous block with plain bupivacaine vs. protracted bupivacaine mixture as a supplement to continuos sciatic catheter after major ankle and foot surgery: a randomized study
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-01-07
The effect of saphenous nerve and obturator nerve block combined with systemic high dose glucocorticoid versus local infiltration analgesia combined with a systemic high dose glucocorticoid on opioid consumption and pain after total knee arthroplasty.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2014-10-01
Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest
CTID: null
Phase: Phase 3    Status: Completed
Date: 2014-07-09
Adrenaline versus amiodarone for out of hospital cardiac arrest due to shockable rhythms (ventricular fibrillation and pulseless ventricular tachycardia) - ADRAMIO.
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2014-06-23
Perioperative Analgesia for Knee Arthroplasty: A prospective randomised controlled trial
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-10-23
Postoperative pain relief following total hip arthroplasty.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-01-02
Effect of local anesthesia in patients with marginal periodontitis undergoing subgingival scaling
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2012-11-15
The effect of intraoperative low dose adrenaline on bleeding in total hip arthroplasty - a randomized placebo-controlled trial
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-09-13
Påverkar valet av smärtlindring vid tjocktarm/ändtarmscancer recidiv och överlevnad? (EPICOL-studien).
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-11-29
Comparación de la efectividad analgésica del bloqueo femoral, la infiltración intraarticular o la combinación de ambas en el control del dolor en la artroplastia total de rodilla.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-09-19
Pain treatment after anterior cruciate ligament reconstruction - Comparison of infiltration analgesia with femoral nerve block after hamstrings anterior cruciate ligament reconstruction.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-10-19
TREATMENT OF HYPOTENSION IN EXTREMELY PRETERM INFANTS: A MULTICENTER RANDOMIZED CONTROLLED TRIAL
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2010-04-13
Optimisation du traitement du choc cardiogénique. Etude pilote physiopathologique ouverte multicentrique comparant l’efficacité et la tolérance de l’adrénaline et la noradrénaline (Optima CC)
CTID: null
Phase: Phase 4    Status: Completed
Date: 2010-03-22
An assessment of the effects of pressors on graft blood flow after free tissue transfer surgery: A randomised study – Part II
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2010-02-08
Multimodal drug infiltration during bone marrow aspiration. A randomized dubble blind controlled study
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2009-09-09
Plasma concentration of Ropivacain and Ketorolac after local infiltration during surgery in hip replacement during the first 24 postoperative hours.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2009-06-17
En dubbel-blind randomiserad studie i postoperativ smärtlindring och mobilisering efter att intrathekal morfin- eller lokal infiltrativ analgesi (LIA)-teknik används vid total knäproteskirurgi.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2009-04-24
Postoperative Pain Relief following Total Hip Arthroplasty.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2009-04-22
Analgesic efficacy of ultrasound guided transversus abdominis plane block as part of a multimodal analgesic regime for post elective caesarean section pain – a comparative double-blinded placebo controlled trial using plain bupivacaine, bupivacaine with adrenaline and bupivacaine with dexamethasone.
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2009-01-29
Postoperative smerter efter bækkenosteotomi med lokal infiltrationsanalgesi hos børn med cerebral parese. Et prospektivt, randomiseret og dobbeltblindet studie.
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2009-01-20
Assessment of the effects of pressors on graft blood flow after free tissue transfer surgery
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-09-24
Undersøgelse af ketorolac i den postoperative smertebehandling efter total knæalloplastik
CTID: null
Phase: Phase 4    Status: Completed
Date: 2008-09-16
A comparative, double blind trial between'older' and 'newer' local anesthetics in forefoot surgery under echographic popliteal block.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-10-29
Postoperative epidural analgesia with Breivik's mixture (bupivacain, fentanyl, epinephrine) compared to Narop (rupivacain) combined with oral oxycodon after posterior lumbar fusion.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2007-08-10
Smärtskattning av adrenalinpenna
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2007-03-08
Epidural analgesia or opatient controlled regional analgesia for radical Retropubic Prostatectomy. A randomized, double-blind study.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2007-01-24
Evaluación de la profundidad anestésica de la lidocaína 1:100.000 frente a la articaína 1:100.000, en la cirugía del tercer molar inferior. Estudio comparativo
CTID: null
Phase: Phase 4    Status: Completed
Date: 2006-11-29
Postoperative pain relief for primary total knee arthroplasty: A randomised clinical trial of local infiltration anaesthesia followed by intraaticulary infusion compared to epidural infusion
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2006-11-21
A comparison of two methodes for pastoperative paintreatment after knee replacement. Pharmacokinetics and clinical effect of femoral block and local infiltration of the operation area of ropivacaine.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2006-10-10
Postoperativ smärtlindring och mobilisering efter per- och postoperativ injektion av ropivakain, ketorolak och adrenalin givet i operationsområdet, infiltrativt och i knäleden, vid total knäplastikoperation.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2006-10-04
“The efficacy of inferior alveolar nerve block and buccal infiltration for pulp anaesthesia in mandibular teeth”
CTID: null
Phase: Phase 4    Status: Completed
Date: 2006-07-31
Kan risikoen for RD og hypoglykæmi efter elektivt sectio reduceres ved indgift af adrenalin.
CTID: null
Phase:    Status: Completed
Date: 2006-04-28
A randomised comparison of 0.5% levobupivacaine with a lidocaine/epinephrine/ fentanyl mixture for epidural top up for emergency caesarean section after “low dose” epidural for labour
CTID: null
Phase: Phase 4    Status: Completed
Date: 2006-04-26
Bupivacaína en anestesia odontológica. Estudio comparativo, respecto a la articaína, de su eficacia clínica durante la extracción quirúrgica del tercer molar inferior incluido.
CTID: null
Phase: Phase 1, Phase 4    Status: Ongoing
Date: 2006-03-01
Effects of Adrenaline on gastric tube blood flow in patients having thoracic epidural for Oesophagogastrectomy
CTID: null
Phase: Phase 4    Status: Completed
Date: 2006-01-16
Postoperativ smärtlindring och mobilisering efter per- och postoperativ injektion av ropivakin, ketorolak och adrenalin givet i operationsområdet, infiltrativt och i knäleden, vid enkammarknäplastikoperation (miniknä)
CTID: null
Phase: Phase 3    Status: Completed
Date: 2005-05-18
Effect of dexmedetomidine on the local anesthetic action
CTID: UMIN000025928
Phase:    Status: Complete: follow-up continuing
Date: 2017-02-01
Clinical Study of autologous blood injection for the treatment of recurrent temporomandibular joint dislocation
CTID: UMIN000022197
PhaseNot applicable    Status: Recruiting
Date: 2016-05-09
A randomized controlled trial comparing continuous femoral nerve block and local infiltration analgesiafor total knee arthroplasty
CTID: UMIN000018850
Phase:    Status: Complete: follow-up complete
Date: 2015-08-29
Effect of Subcutaneous Epinephrine/Saline/Local Anesthetic Versus Saline-Only Injection on Split-Thickness Skin Graft Donor Site
CTID: UMIN000018448
Phase:    Status: Complete: follow-up complete
Date: 2015-08-01
Observation of the upper gastrointestinal tract lesions by epinephrine spraying
CTID: UMIN000017722
Phase:    Status: Complete: follow-up complete
Date: 2015-05-28
The study to prevent and reduce postoperative nausea and vomiting due to continuous epidural administration
CTID: UMIN000017055
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2015-04-06
Non-inferiority trial of cardiovascular dynamics of lidocaine with adrenaline injection under general anesthesia between antipsychotics patients and control patients
CTID: UMIN000016644
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2015-04-01
Effect of dexmedetomidine on the local anesthetic action
CTID: UMIN000016224
Phase:    Status: Complete: follow-up continuing
Date: 2015-01-15
study of the efficacy of the Levobupivacaine in mandibular-foramen conduction anesthesia
CTID: UMIN000009341
Phase:    Status: Pending
Date: 2012-11-30
Study of pain control on Impacted Mandibular Third Molar
CTID: UMIN000007831
Phase:    Status: Complete: follow-up complete
Date: 2012-04-25
Effect of steroidmixed injection to submucosa during ESD on the epithelial regeneration promoting action of postoperative artificial ulcer following endoscopic submucosal dissection in early-stage gastric cancer - Preventing stomach deformation due to scar formation during the epithelial regeneration process
CTID: UMIN000007588
Phase:    Status: Pending
Date: 2012-03-28
The study of physiological stress and recovery condition between AOP vs. TIVA for ambulatory general anesthesia to dental patient -Salivary alpha-amylase level and activity of autonomic nervous system were measured for mental retardation and autism patient-
CTID: UMIN000005615
Phase: Phase IV    Status: Complete: follow-up complete
Date: 2011-05-17
Study of pain control on Impacted Mandibular Third Molar
CTID: UMIN000002596
Phase:    Status: Complete: follow-up continuing
Date: 2009-10-07
Effects of fentanyl added to mepivacaine for inferior alveolar nerve block duration, double blind, randomized trial
CTID: UMIN000002540
Phase: Phase IV    Status: Complete: follow-up complete
Date: 2009-09-24
Axillary block and local anesthesia for postoperative pain control after elbow arthroscopy: A randomized controlled trial
CTID: UMIN000002275
Phase:    Status: Complete: follow-up complete
Date: 2009-08-01
comparison between endoscopic clipping and combination of endoscopic clipping and injection for gastric ulcer bleeding: a prospective randomized controlled trial
CTID: UMIN000001978
PhaseNot applicable    Status: Complete: follow-up complete
Date: 2009-05-16

Contact Us